Agent Orange Exposure, Cytogenetics, and Clinical Outcomes in Multiple Myeloma and MGUS Patients

被引:0
|
作者
Kulkami, P. [1 ,2 ]
Hall, J. A. [1 ,2 ]
Copeland, L. A. [3 ,4 ]
Nangrani, A. [1 ]
Dodlapati, J. [1 ,2 ]
机构
[1] Cent Texas Vet Hlth Care Syst, Temple, TX USA
[2] Baylor Scott & White Hlth, Dallas, TX USA
[3] VA Cent Western Massachusetts Healthcare Syst, Northampton, MA 01062 USA
[4] Univ Massachusetts, Chan Med Sch, Worcester, MA 01106 USA
来源
关键词
MONOCLONAL GAMMOPATHY; POOR-PROGNOSIS; LONG-TERM; CHROMOSOME-13; DELETION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background While considerable research has examined transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) and the association of Agent Orange (AO) with MM, adverse cytogenetics are understudied. Purpose To evaluate associations between AO and adverse cytogenetics or other poor prognostic factors such as abnormal light chain ratio in aged veterans with MM. Materials and methods Vietnam -era Veterans diagnosed with MM or MGUS at a Veterans Health Administration site were identified. Chart review abstracted presence of 17p13, t(4;14), t(14;16), t(14;20), and Gain lq by FISH (dubbed FISH-5) and q13/13q14 deletion, kappa/lambda ratio <.03 / >32 for MM (<.256 / >1.65 for MGUS), and bone marrow plasma cell percentage for MM. Results Among 238 veterans, 70 had MM and 192 MGUS; 24 had both diagnoses (transformation). In MGUS, AO was not associated with transformation, although kappa/lambda ratio was. In MM, Hispanic veterans had more AO exposure. Survival was unassociated with AO or adverse cytogenetics, while Hispanic veterans experienced increased mortality. Conclusion Our study explored cytogenetics in MM among surviving Vietnam Veterans with and without AO exposure. Although Hispanic veterans were more likely to have AO exposure, Hispanic ethnicity but not AO was associated with poorer survival.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [41] Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy
    Nandakumar, Bharat
    Kumar, Shaji K.
    Dispenzieri, Angela
    Buadi, Francis K.
    Dingli, David
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Leung, Nelson
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi Lisa
    Muchtar, Eli
    Warsame, Rahma
    Kourelis, Taxiarchis V.
    Russell, Stephen
    Lust, John A.
    Lin, Yi
    Go, Ronald S.
    Siddiqui, Mustaqeem
    Zeldenrust, Steven
    Kyle, Robert A.
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Gonsalves, Wilson I.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01): : 53 - 56
  • [42] Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients
    Lee, Sung-Eun
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Kim, Myungshin
    Min, Chang-Ki
    THROMBOSIS RESEARCH, 2015, 136 (05) : 974 - 979
  • [43] Management Patterns and Outcomes for Multiple Myeloma Patients with High-Risk Cytogenetics at an Urban Safety Net Hospital
    Yashar, David
    Tomassetti, Sarah
    Leong, Sally
    BLOOD, 2023, 142
  • [44] Clinical Characteristics of Ischemic Stroke with Previous Exposure to Agent Orange
    Ha, S. W.
    Hwang, J. Y.
    CEREBROVASCULAR DISEASES, 2013, 35 : 437 - 437
  • [45] Clinical Characteristics of Ischemic Stroke with Previous Exposure to Agent Orange
    Ha, S. W.
    Hwang, J. Y.
    CEREBROVASCULAR DISEASES, 2013, 35 : 444 - 444
  • [46] PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    HAEMATOLOGICA, 2016, 101 : 263 - 264
  • [47] MOLECULAR CYTOGENETICS STUDY OF MULTIPLE MYELOMA ABOUT 30 TUNISIAN PATIENTS
    Tabka, I.
    Bennour, A.
    Ben Youssef, Y.
    Zaier, M.
    Kmira, Z.
    Elloumi, M.
    Khelif, A.
    Saad, A.
    Sennana, H.
    HAEMATOLOGICA, 2012, 97 : 548 - 548
  • [48] The Effect and the Cost of Tandem Transplantation in Multiple Myeloma Patients with Adverse Cytogenetics
    Komuro, Masato
    Kondo, Naoki
    Hagiwara, Shotaro
    Kuwahara, Takeshi
    Tanaka, Junji
    BLOOD, 2017, 130
  • [49] The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study
    Liu, Lawrence
    Wang, Mei
    Grandhi, Nikhil
    Schroeder, Mark A.
    Thomas, Theodore S.
    Kumar, Akhil
    Vargo, Kristin
    Gao, Feng
    Sanfilippo, Kristen M.
    Chang, Su-Hsin
    BLOOD, 2022, 140 : 4356 - 4357
  • [50] The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Bahlis, Nizar J.
    Song, Kevin W.
    Fu, Tommy
    Roland, Birgitte J.
    Chang, Hong
    Horsman, Doug
    Mansoor, Adnan
    Chen, Christine
    Masih-Khan, Esther
    Trieu, Young
    Bruyere, Helene
    Stewart, Douglas A.
    Reece, Donna E.
    BLOOD, 2008, 112 (11) : 610 - 610